KTX-951 is a PROTAC designed to selectively degrade IRAK4, demonstrating effective performance in cellular assays. This compound exhibits notable oral bioavailability in preclinical models, indicating its potential for effective systemic delivery. Additionally, KTX-951 shows promise in anticancer applications due to its mechanism of action.
Usually ships within 24 hours.